VA expands medication consent policy

Summary#

The Written Informed Consent Act would amend no statute; it would direct the Secretary of Veterans Affairs to update an existing Veterans Health Administration (VHA) directive. The stated goal is to extend that directive, which concerns informed consent for long-term opioid therapy, to five additional medication categories. The bill has been introduced but is not law.

  • The Secretary must update the directive to apply to antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics.
  • The bill does not create a new agency or set out the consent steps itself; it expands the scope of an existing VHA directive.
  • The bill does not state whether the directive would apply to every use of these medications or set out exceptions.

What it means for you#

  • Veterans receiving care through VHA: The directive would apply to the listed medication categories as well as long-term opioid therapy. The bill does not say exactly what consent patients would have to give or whether it must be written.
  • The Secretary of Veterans Affairs: Must update the directive. The bill does not set a deadline.
  • VA staff: They may have to follow the updated directive, but the bill does not specify what procedures or training that would involve.
  • People outside VHA: The bill does not directly change medication consent rules for non-VA care.

Money#

No publicly available information on cost.

  • The bill provides no cost estimate or specific funding for updating or carrying out the directive.

What is unclear#

  • The existing VHA directive is not included in the supplied material, so its current consent requirements—and what would change in practice—could not be verified.
  • The bill does not define the listed medication categories or explain which uses of those medications would be covered.
  • It does not specify what information must be given, whether consent must be written, how often consent is needed, or whether there are exceptions.
  • It sets no deadline, oversight rules, or process for resolving questions about the updated directive.

Case for#

  • The bill appears intended to extend an informed-consent policy beyond long-term opioid therapy to other named medication categories.
  • A possible argument for the bill is that applying the directive to more medication types could give VA patients a more consistent consent process.
  • Requiring the Secretary to update an existing directive may use an established VHA policy rather than create a new agency.

Case against#

  • The bill does not specify what patients must be told or what counts as informed consent, leaving the practical effect to the updated directive.
  • The medication categories are broad and undefined in the bill, so the scope of the change is uncertain.
  • Without stated exceptions or details about how consent works, the update could add steps for patients and VA staff without making clear when those steps apply.